Dr. Lal Path Labs share news, announcements and annual reports
NSE: LALPATHLABBSE: 539524Healthcare ServicesSmall Cap
Dr. Lal Path Labs Ltd. · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2015
Last close ₹1,922.30up ₹20.50 (1.08%)BSE ₹1,920.75
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,901.80.
28 Oct: open ₹1,885.20, high ₹1,936.50, low ₹1,871.00
52-week range of traded prices to 28 Oct 2026
₹1,272.60Low, 23 Mar 2026₹2,038.60High, 16 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results, other business matters and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹32,266 Cr309th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 59.54
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 12.86
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.83%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 23.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 26.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,24,17959.9% delivered
Dr. Lal Path Labs has 866 announcements on record, routine notices left out; 5 in the 30 days to 29 Oct 2026, the latest on 27 Oct 2026.
Next board meeting and results date
As the company gave notice to the exchange.Dr. Lal Path Labs quarterly results
Nov4Wed
The board meets on 4 Nov 2026 to consider financial results, other business matters and dividend
Notice filed 25 Sep 2026
Dr. Lal Path Labs annual reports, presentations and earnings calls
The company's own documents, latest first.Dr. Lal Path Labs financials, year by year
Annual reports11
- Annual report, year to Mar 20261 Jul 2026
- Annual report, year to Mar 20254 Jun 2025
- Annual report, year to Mar 20244 Jun 2024
- Annual report, year to Mar 202317 Aug 2023, a zip file
- Annual report, year to Mar 20227 Jun 2022, a zip file
6 earlier reports
- Annual report, year to Mar 20216 Jul 2021, a zip file
- Annual report, year to Mar 20207 Jul 2020, a zip file
- Annual report, year to Mar 201911 Jul 2019, a zip file
- Annual report, year to Mar 201817 Aug 2018, a zip file
- Annual report, year to Mar 201721 Jul 2017, a zip file
- Annual report, year to Mar 201628 Jul 2016, a zip file
Investor presentations71
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation24 Jul 2026
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation30 Apr 2026
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation30 Jan 2026
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation31 Oct 2025
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation31 Jul 2025
66 earlier presentations
- Dr. Lal Path Labs Ltd. has informed the Exchange about Presentation25 Apr 2025
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation30 Jan 2025
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation23 Oct 2024
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation7 Aug 2024
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation20 May 2024
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation10 May 2024
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation10 May 2024
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation1 Feb 2024
- Dr. Lal Path Labs Ltd. has informed the Exchange about Presentation2 Nov 2023
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation27 Jul 2023
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation11 May 2023
- Dr. Lal Path Labs Ltd. has informed the Exchange about Presentation2 Feb 2023
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation.8 Nov 2022
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation for Q1 FY 2022-23.28 Jul 2022
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation.23 May 2022
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation Q4 & FY2217 May 2022
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation10 Feb 2022
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation26 Oct 2021
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation30 Jul 2021
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation24 May 2021
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation21 May 2021
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation5 Feb 2021
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation29 Jan 2021
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation13 Nov 2020
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation6 Nov 2020
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation5 Aug 2020
- Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation31 Jul 2020
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation20 May 2020
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation18 May 2020
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation11 Feb 2020
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation3 Feb 2020
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation13 Nov 2019
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation8 Nov 2019
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation19 Aug 2019
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation13 Aug 2019
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation for Financial Year 2018-1923 May 2019
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation17 May 2019
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation15 Feb 2019
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation8 Feb 2019
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation12 Nov 2018
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation6 Nov 2018
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation16 Aug 2018, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation10 Aug 2018, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding 'Revised Corporate Presentation Q4 FY18.'29 May 2018, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding 'Corporate Presentation for Q4 FY17'.28 May 2018, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation14 May 2018, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation19 Feb 2018, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation9 Feb 2018, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation8 Feb 2018, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation10 Nov 2017, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation9 Nov 2017, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation19 Sep 2017, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation7 Aug 2017, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation2 Jun 2017, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation12 May 2017, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Corporate Presentation for quarter and nine year ended December 31, 2016.3 Feb 2017, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation2 Feb 2017, a zip file
- Dr. Lal Path Labs Ltd. has submitted to the Exchange a Copy of Corporate Presentation of the Company for Q2 H1 FY 17.4 Nov 2016, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation3 Nov 2016, a zip file
- Dr. Lal Path Labs Ltd. has submitted to the Exchange a Copy of Corporate Presentation of the Company.2 Sep 2016, a zip file
- Dr. Lal Path Labs Ltd. has submitted to the Exchange a copy of the Corporate Presentation of the Company for Q1 FY 17.29 Aug 2016, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Q1 FY17 Results Presentation July 29, 2016.29 Jul 2016, a zip file
- Dr. Lal Path Labs Ltd. has submitted to the Exchange a copy of Corporate Presentation of the Company for Q4/FY 16.7 Jun 2016, a zip file
- Dr. Lal Path Labs Ltd. has submitted to the Exchange a copy of Company s Q4/FY16 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Audited Financial Results (Standalone and Consolidated) for the Quarter and Year ended March 31, 2016, approved by the Board of Directors in their meeting held on May 27, 2016.27 May 2016, a zip file
- Dr. Lal Path Labs Ltd. has submitted to the Exchange a copy of Corporate Presentation of the Company.22 Feb 2016, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Earnings Presentation.13 Feb 2016, a zip file
Earnings calls43
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript30 Jul 2026
- Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording24 Jul 2026
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript6 May 2026
- Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording30 Apr 2026
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript3 Feb 2026
38 earlier call documents
- Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording30 Jan 2026
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript6 Nov 2025
- Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording31 Oct 2025
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript5 Aug 2025
- Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording31 Jul 2025
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript1 May 2025
- Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording25 Apr 2025
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript3 Feb 2025
- Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording30 Jan 2025
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript28 Oct 2024
- Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording23 Oct 2024
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript13 Aug 2024
- Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording7 Aug 2024
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript15 May 2024
- Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording10 May 2024
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript7 Feb 2024
- Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording1 Feb 2024
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript8 Nov 2023
- Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording2 Nov 2023
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript2 Aug 2023
- Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording of the Company Conference Call dated July 27, 2023 with Investors/ Analysts for Q1 FY24.27 Jul 2023
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript16 May 2023
- Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording11 May 2023
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript8 Feb 2023
- Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording2 Feb 2023
- Dr. Lal Path Labs Ltd. has informed the Exchange about the Transcript of Analysts/Institutional Investor Meet/Con. Call.14 Nov 2022
- Dr. Lal Path Labs Ltd. has informed the Exchange about Recording of Analysts/Institutional Investor Meet/Con. Call.8 Nov 2022
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript of Analysts/Institutional Investor Meet/Con. Call.3 Aug 2022
- Dr. Lal Path Labs Ltd. has informed the Exchange about Recording of Analysts/Institutional Investor Meet/Con. Call.28 Jul 2022
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript of Analysts/Institutional Investor Meet/Con. Call.23 May 2022
- Dr. Lal Path Labs Ltd. has informed the Exchange about Recording of Analysts/Institutional Investor Meet/Con. Call17 May 2022
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript of Analysts/Institutional Investor Meet/Con. Call25 Feb 2022
- Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript15 Nov 2021
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates:Financial Results Conference Call Transcript of the Company for Q3 & 9M FY2017 Feb 2020
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates : Financial Result Conference Call Transcript of the Company for Q2 & H1 FY20.25 Nov 2019
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Financial Results Conference Call Transcript of the Company for Q1 FY17.9 Aug 2016, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Q4 & FY16 Results Conference Call Transcript May 27, 2016.9 Jun 2016, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Financial Results Conference Call Transcript of the Company for Q3 & 9M FY16.23 Feb 2016, a zip file
Dr. Lal Path Labs merger and demerger filings
Filings about a merger, demerger or scheme of arrangement, latest first.
Filings9
- Dr. Lal Path Labs Ltd has informed the Exchange that Hon'ble National Company Law Tribunal ( NCLT ), Ahmedabad Bench-Il has, vide its order dated March 17, 2023, sanctioned the Scheme of Amalgamation between Dr. Lal PathLabs Limited ( Transferee Company ) and APL Institute of Clinical Laboratory & Research Private Limited ( Transferor Company ), a wholly owned subsidiary of Transferee Company.17 Mar 2023
- In furtherance to Company's letters dated February 3, 2020 and February 11, 2020 and in terms of Regulation 30 read with Regulation 37 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that Hon'ble National Company Law Tribunal ( NCLT), New Delhi Bench-Ill has, vide its order dated May 13, 2022, sanctioned the Scheme of Amalgamation between Dr. Lal PathLabs Limited ( The transferee Company) and APL Institute of Clinical Laboratory & Research Private Limited ( The transferor Company), a wholly owned subsidiary of the transferee Company. The said sanction, however, is subject to the approval of scheme by NCLT, Ahmedabad also.13 May 2022
- Dr. Lal Path Labs Ltd. has informed the Exchange about scheme of Amalgamation/Merger11 Feb 2020
- Dr. Lal Path Labs Ltd. has informed the Exchange about Amalgamation/Merger3 Feb 2020
- Dr. Lal Path Labs Ltd. has informed the Exchange that this is in furtherance to letter dated December 14, 2018, wherein the Company informed that Hon ble National Company Law Tribunal ("NCLT"), Ahmedabad Bench, sanctioned the Scheme of Amalgamation between Dr. Lal PathLabs Limited ("The transferee Company") and Delta Ria and Pathology Private Limited ("The transferor Company"), a wholly owned subsidiary of the transferee Company. Please take note that consequent upon filing of ROC intimation on January 1, 2019, the Scheme has become effective. Accordingly January 1, 2019 becomes the effective date for the said Scheme of Amalgamation.2 Jan 2019
4 earlier filings
- Dr. Lal Path Labs Ltd. has informed the Exchange that Hon'ble National Company Law Tribunal ("NCLT"), Ahmedabad Bench has sanctioned the Scheme of Amalgamation between Dr. Lal PathLabs Limited ("The transferee Company") and Delta Ria and Pathology Private Limited ("The transferor Company"), a wholly owned subsidiary of the transferee Company.14 Dec 2018
- Dr. Lal Path Labs Ltd. has informed the Exchange that Hon ble National Company Law Tribunal ( NCLT), New Delhi Bench-III has sanctioned the Scheme of Amalgamation between Dr. Lal PathLabs Limited ( The transferee Company) and Delta Ria and Pathology Private Limited ( The transferor Company), a wholly owned subsidiary of the transferee Company. The said sanction, however, is subject to the approval of scheme by NCLT, Ahmedabad also.26 Oct 2018
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Disclosure of Scheme of Amalgamation pursuant to Regulation 37 of the SEBI ( Listing Obligation & Disclosure Requirements) Regulations, 2015.29 Nov 2017, a zip file
- Dr. Lal Path Labs Ltd. has informed the Exchange that the Board of Directors in their meeting held on May 12, 2017 , approved the Scheme of Amalgamation of Delta Ria and Pathology Private Limited ( the Transferor Company ), a wholly owned subsidiary of Dr. Lal PathLabs Ltd. ("Company") with the Company with effect from April 01, 2017 ( Appointed Date ), pursuant to sections 230-232 of the Companies Act, 2013. The scheme is conditional upon and subject, inter alia, to sanction of the same by the Hon ble National Company Law Tribunal ( NCLT ).12 May 2017, a zip file
Dr. Lal Path Labs share news and announcements
Newest first. Page 1 of 18.
Oct 2026
13 Oct · General Updates
12 Oct · General Updates
8 Oct · General Updates
1 Oct · General Updates
Sep 2026
Aug 2026
27 Aug · General Updates
19 Aug · General Updates
Jul 2026
Jun 2026
May 2026
Apr 2026
Mar 2026
Feb 2026
Jan 2026
23 Jan · Board meeting
Dec 2025
8 Dec · Amendment to AOA/MOA
How the price met the news
The latest 30. The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 24 Jul 2026Resultsup 4.27%+4.6 pts vs Nifty 500market median −0.7% · five sessions +11.4% (+9.7 pts vs Nifty 500) · volume 4.7× usual · delivery −24.5 pts against usual · The announcement
- 30 Apr 2026Resultsdown 2.19%−1.4 pts vs Nifty 500market median −0.7% · five sessions +12.0% (+10.5 pts vs Nifty 500) · volume 0.9× usual · delivery −7.6 pts against usual · The announcement
- 27 Mar 2026Credit ratingdown 1.57%+0.6 pts vs Nifty 500market median 0.0% · five sessions +0.4% (+1.7 pts vs Nifty 500) · volume 0.8× usual · delivery −2.8 pts against usual · The announcement
- 30 Jan 2026Resultsup 1.02%+1.3 pts vs Nifty 500market median −0.7% · five sessions +0.8% (−0.9 pts vs Nifty 500) · volume 1.2× usual · delivery −20.0 pts against usual · The announcement
- 23 Jan 2026Dividenddown 2.93%−1.6 pts vs Nifty 500market median 0.0% · five sessions −0.6% (−0.9 pts vs Nifty 500) · volume 1.1× usual · delivery +5.2 pts against usual · The announcement
- 31 Oct 2025Resultsup 1.49%+2.0 pts vs Nifty 500market median −0.7% · five sessions +0.2% (+1.6 pts vs Nifty 500) · volume 4.7× usual · delivery −32.4 pts against usual · The announcement
- 31 Jul 2025Resultsup 1.67%+2.2 pts vs Nifty 500market median −0.7% · five sessions +3.5% (+5.1 pts vs Nifty 500) · volume 1.9× usual · delivery −30.4 pts against usual · The announcement
- 25 Apr 2025Resultsup 4.41%+5.9 pts vs Nifty 500market median −0.7% · five sessions +0.2% (+1.0 pts vs Nifty 500) · volume 5.1× usual · delivery −32.8 pts against usual · The announcement
- 25 Apr 2025Dividendup 4.41%+5.9 pts vs Nifty 500market median 0.0% · five sessions +0.2% (+1.0 pts vs Nifty 500) · volume 5.1× usual · delivery −32.8 pts against usual · The announcement
- 23 Apr 2025Credit ratingup 0.22%−0.5 pts vs Nifty 500market median 0.0% · five sessions +0.6% (+0.4 pts vs Nifty 500) · volume 0.2× usual · delivery −0.5 pts against usual · The announcement
20 earlier announcements
- 1 Apr 2025Board or managers changeddown 3.20%−1.9 pts vs Nifty 500market median 0.0% · five sessions −0.6% (+5.1 pts vs Nifty 500) · volume 2.3× usual · delivery +13.3 pts against usual · The announcement
- 17 Mar 2025Credit ratingup 0.72%+0.2 pts vs Nifty 500market median 0.0% · five sessions +0.3% (−5.1 pts vs Nifty 500) · volume 0.5× usual · delivery +13.7 pts against usual · The announcement
- 30 Jan 2025Resultsup 4.31%+4.1 pts vs Nifty 500market median −0.7% · five sessions +2.6% (+0.3 pts vs Nifty 500) · volume 3.6× usual · delivery +9.4 pts against usual · The announcement
- 30 Jan 2025Dividendup 4.31%+4.1 pts vs Nifty 500market median 0.0% · five sessions +2.6% (+0.3 pts vs Nifty 500) · volume 3.6× usual · delivery +9.4 pts against usual · The announcement
- 24 Oct 2024Resultsdown 6.35%−6.1 pts vs Nifty 500market median −0.7% · five sessions −6.5% (−6.1 pts vs Nifty 500) · volume 6.0× usual · delivery −25.5 pts against usual · The announcement
- 24 Oct 2024Dividenddown 6.35%−6.1 pts vs Nifty 500market median 0.0% · five sessions −6.5% (−6.1 pts vs Nifty 500) · volume 6.0× usual · delivery −25.5 pts against usual · The announcement
- 24 Oct 2024Board or managers changeddown 6.35%−6.1 pts vs Nifty 500market median 0.0% · five sessions −6.5% (−6.1 pts vs Nifty 500) · volume 6.0× usual · delivery −25.5 pts against usual · The announcement
- 7 Aug 2024Resultsup 3.36%+1.5 pts vs Nifty 500market median −0.7% · five sessions +2.8% (+1.6 pts vs Nifty 500) · volume 1.8× usual · delivery −17.0 pts against usual · The announcement
- 7 Aug 2024Dividendup 3.36%+1.5 pts vs Nifty 500market median 0.0% · five sessions +2.8% (+1.6 pts vs Nifty 500) · volume 1.8× usual · delivery −17.0 pts against usual · The announcement
- 10 May 2024Resultsup 5.21%+4.6 pts vs Nifty 500market median −0.7% · five sessions +13.0% (+10.1 pts vs Nifty 500) · volume 3.7× usual · delivery −27.2 pts against usual · The announcement
- 10 May 2024Dividendup 5.21%+4.6 pts vs Nifty 500market median 0.0% · five sessions +13.0% (+10.1 pts vs Nifty 500) · volume 3.7× usual · delivery −27.2 pts against usual · The announcement
- 4 Mar 2024Board or managers changeddown 2.52%−2.6 pts vs Nifty 500market median 0.0% · five sessions −8.2% (−7.5 pts vs Nifty 500) · volume 1.7× usual · delivery +16.5 pts against usual · The announcement
- 14 Feb 2024Credit ratingdown 0.90%−1.6 pts vs Nifty 500market median 0.0% · five sessions −0.2% (−2.7 pts vs Nifty 500) · volume 0.4× usual · delivery −5.8 pts against usual · The announcement
- 1 Feb 2024Dividenddown 0.71%−0.6 pts vs Nifty 500market median 0.0% · five sessions −0.6% (−2.2 pts vs Nifty 500) · volume 2.9× usual · delivery −8.2 pts against usual · The announcement
- 2 Nov 2023Resultsup 3.46%+2.5 pts vs Nifty 500market median −0.7% · five sessions +12.3% (+9.2 pts vs Nifty 500) · volume 3.0× usual · delivery −14.8 pts against usual · The announcement
- 27 Jul 2023Resultsup 2.70%+3.0 pts vs Nifty 500market median −0.7% · five sessions −4.8% (−4.2 pts vs Nifty 500) · volume 2.3× usual · delivery −7.2 pts against usual · The announcement
- 27 Jul 2023Dividendup 2.70%+3.0 pts vs Nifty 500market median 0.0% · five sessions −4.8% (−4.2 pts vs Nifty 500) · volume 2.3× usual · delivery −7.2 pts against usual · The announcement
- 11 May 2023Dividenddown 2.23%−2.3 pts vs Nifty 500market median 0.0% · five sessions +3.3% (+3.5 pts vs Nifty 500) · volume 2.5× usual · delivery −11.6 pts against usual · The announcement
- 11 May 2023Resultsdown 2.23%−2.3 pts vs Nifty 500market median −0.7% · five sessions +3.3% (+3.5 pts vs Nifty 500) · volume 2.5× usual · delivery −11.6 pts against usual · The announcement
- 14 Feb 2023Board or managers changedup 0.99%+0.5 pts vs Nifty 500market median 0.0% · five sessions +0.6% (+0.3 pts vs Nifty 500) · volume 1.0× usual · delivery −1.8 pts against usual · The announcement
Dr. Lal Path Labs results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.